ODC-TARGET E

ODC-TARGET E is a preclinical-stage antibody-drug conjugate (ADC) being developed by Trutino Biosciences for the treatment of autoimmune diseases. The drug is designed to target a specific, undisclosed biological entity referred to as Target E, delivering a therapeutic payload with high precision to modulate immune responses. This program represents an expansion of Trutino's portfolio beyond its core On-Demand Cytokine (ODC) platform into the ADC space for immunological indications. By leveraging the ADC modality, the program aims to provide targeted therapy that improves efficacy while minimizing the systemic side effects often associated with traditional immunosuppressive agents.